Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).

Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A.

Breast Cancer Res Treat. 2007 Jan;101(2):215-23.

PMID:
16823507
2.

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.

Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA.

J Clin Oncol. 2006 Oct 20;24(30):4888-94.

PMID:
17015884
3.
4.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

5.

Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.

Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI.

Breast Cancer Res Treat. 2006 Oct;99(3):313-21.

PMID:
16583264
6.

[Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].

Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.

Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):77-81. Chinese.

PMID:
18353207
7.

Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

Adjuvant Breast Cancer Trials Collaborative Group..

J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.

8.

Does timing of adjuvant chemotherapy for early breast cancer influence survival?

Shannon C, Ashley S, Smith IE.

J Clin Oncol. 2003 Oct 15;21(20):3792-7.

PMID:
14551298
9.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators..

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151.

10.

Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.

Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS.

Breast. 2008 Dec;17(6):646-53. doi: 10.1016/j.breast.2008.05.006.

PMID:
18595699
11.

Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.

Ibrahim EM, Ezzat AA, Rahal MM, Raja MM, Ajarim DS.

Med Oncol. 2005;22(4):343-52.

PMID:
16260851
12.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group.; Scottish Breast Cancer Trials Group..

Eur J Cancer. 2007 Jan;43(2):331-40.

PMID:
17134892
13.

[Impact of the interval between surgery and radiotherapy in the initial phases of breast cancer in patients who did not receive systemic adjuvant therapy].

Bahena J, Labastida Almendaro S, Ayala Hernández JR, Fernández Orozco A.

Ginecol Obstet Mex. 1998 Mar;66:87-91. Spanish.

PMID:
9608183
14.

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.

Chirivella I, Bermejo B, Insa A, Pérez-Fidalgo A, Magro A, Rosello S, García-Garre E, Martín P, Bosch A, Lluch A.

Breast Cancer Res Treat. 2009 Apr;114(3):479-84. doi: 10.1007/s10549-008-0018-1.

PMID:
18463977
15.

Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.

Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI.

Cancer. 2006 Dec 1;107(11):2581-8.

16.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group..

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

17.

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.

18.

Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.

Kennedy T, Stewart AK, Bilimoria KY, Patel-Parekh L, Sener SF, Winchester DP.

Ann Surg Oncol. 2007 Oct;14(10):2918-27.

PMID:
17638060
19.

Optimal timing of adjuvant treatment in patients with early breast cancer.

Alkis N, Durnali AG, Arslan UY, Kocer M, Onder FO, Tokluoglu S, Celenkoglu G, Muallaoglu S, Utkan G, Ulas A, Altundag K.

Med Oncol. 2011 Dec;28(4):1255-9. doi: 10.1007/s12032-010-9566-4.

PMID:
20473647
20.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2.

PMID:
18488249
Items per page

Supplemental Content

Support Center